Silver Book Fact

Because the resource use and direct cost of glaucoma treatment and management increases as the disease severity worsens– from an average $623 per early-stage patient to $2,511 per late-stage patient– a glaucoma treatment that delays the disease progression could significantly reduce its economic burden.

Lee P, Walt J, Doyle J, Kotak S, et al. A Multicenter, Retrospective Pilot Study of Resource Use and Costs Associated with Severity of Disease in Glaucoma. Archives of Ophthalmology. 2006; 124(1): 12-9. http://archopht.ama-assn.org/cgi/content/abstract/124/1/12

Reference

Title
A Multicenter, Retrospective Pilot Study of Resource Use and Costs Associated with Severity of Disease in Glaucoma
Publication
Archives of Ophthalmology
Publication Date
2006
Authors
Lee P, Walt J, Doyle J, Kotak S, et al.
Volume & Issue
Volume 124, Issue 1
Pages
12-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Screening and treatment of diabetic retinopathy in type 2 diabetes patients produces annual savings of $247.9 million to the federal budget– in 1994 dollars.  
  • Gene transfer process treatment for diabetic retinopathy
    A gene transfer process that produces a VEGF receptor prevents retinal vascular permeability (RVP) associated with diabetes that could have value in treating diabetic retinopathy.  
  • Multifocal electroretinogram (mFERG) and flicker perimetry show abnormal function in the central macula in early ag-related macular degeneration (AMD) and could enhance monitoring of the disease progression in individuals.  
  • Of the 8 million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years. However, the NEI-sponsored Age-Related Eye…  
  • The NEI-sponsored Age-Related Eye Disease Study (AREDS) found that individuals at high risk of developing advanced stages of age-related macular degeneration (AMD) lowered their risk of disease progression by about…